Patents by Inventor Richard Lee Walter

Richard Lee Walter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8512972
    Abstract: The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: August 20, 2013
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Artem Gennady Evdokimov, Richard Masaru Kawamoto, Angelique Sun Boyer, Marlene Jan Mekel, Matthew Eugene Pokross, Richard Lee Walter, Jr.
  • Publication number: 20120282627
    Abstract: The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.
    Type: Application
    Filed: September 12, 2011
    Publication date: November 8, 2012
    Inventors: Artem Gennady Evdokimov, Richard Masaru Kawamoto, Angelique Sun Boyer, Marlene Jan Mekel, Matthew Eugene Pokross, Richard Lee Walter, JR.
  • Patent number: 8050873
    Abstract: The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: November 1, 2011
    Assignee: Warner Chilcott Company
    Inventors: Artem Gennady Evdokimov, Richard Masaru Kawamoto, Angelique Sun Boyer, Marlene Jan Mekel, Matthew Eugene Pokross, Richard Lee Walter, Jr.
  • Publication number: 20090240475
    Abstract: The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.
    Type: Application
    Filed: May 28, 2009
    Publication date: September 24, 2009
    Inventors: ARTEM GENNADY EVDOKIMOV, RICHARD MASARU KAWAMOTO, SUN BOYER, MERLENE JAN MEKEL, METTHEW EUGENE POKROSS, RICHARD LEE WALTER, JR.
  • Patent number: 7588924
    Abstract: The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: September 15, 2009
    Assignee: Procter & Gamble Company
    Inventors: Artem Gennady Evdokimov, Richard Masaru Kawamoto, Angelique Sun Boyer, Marlene Jan Mekel, Matthew Eugene Pokross, Richard Lee Walter, Jr.
  • Publication number: 20080124740
    Abstract: The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.
    Type: Application
    Filed: March 5, 2007
    Publication date: May 29, 2008
    Inventors: Artem Gennady Evdokimov, Richard Masaru Kawamoto, Angelique Sun Boyer, Marlene Jan Mekel, Matthew Eugene Pokross, Richard Lee Walter
  • Patent number: 6897033
    Abstract: Disclosed is a novel polypeptide having an amino acid sequence substantially as shown in SEQ ID NO:2, or substantially similar to the amino acid sequence encoded by the DNA insert contained in ATCC Deposit No. PTA-4086. Also disclosed is an isolated polynucleotide substantially as shown in SEQ ID NO:1, or substantially similar to a nucleotide sequence contained in a plasmid having all of the identifying characteristics of ATCC Deposit No PTA-4086, encoding the polypeptide. Further disclosed is an expression system comprising the above polynucleotide.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: May 24, 2005
    Assignee: The Procter & Gamble Company
    Inventors: Thomas Larry Dawson, Yvonne Marie Deangelis, Kevin Robert Johnstone, Joseph Robert Kaczvinsky, Jr., Charles Winston Saunders, Richard Lee Walter, Jr.
  • Publication number: 20030158385
    Abstract: Disclosed is a novel polypeptide having an amino acid sequence substantially as shown in SEQ ID NO:2, or substantially similar to the amino acid sequence encoded by the DNA insert contained in ATCC Deposit No. PTA-4086. Also disclosed is an isolated polynucleotide substantially as shown in SEQ ID NO:1, or substantially similar to a nucleotide sequence contained in a plasmid having all of the identifying characteristics of ATCC Deposit No PTA-4086, encoding the polypeptide. Further disclosed is an expression system comprising the above polynucleotide.
    Type: Application
    Filed: February 19, 2003
    Publication date: August 21, 2003
    Applicant: The Procter & Gamble Company
    Inventors: Thomas Larry Dawson, Yvonne Marie Deangelis, Kevin Robert Johnstone, Joseph Robert Kaczvinsky, Charles Winston Saunders, Richard Lee Walter
  • Patent number: D794921
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: August 22, 2017
    Inventor: Richard Lee Walters